Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide

Detalhes bibliográficos
Autor(a) principal: Mesquita,Rafael Carvalho
Data de Publicação: 2007
Outros Autores: Souza,Lívia Noronha Coelho de, Bruin,Pedro Felipe Carvalhedo de, Carvalho,Raquel Ribeiro, Medeiros,Marta Maria das Chagas, Rocha,Francisco Airton Castro da, Bruin,Veralice Meireles Sales de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Reumatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042007000600002
Resumo: BACKGROUND: Pulse i.v. cyclophosphamide is a therapeutic option in severe forms of systemic lupus erythematosus (SLE). However, the overall toxicity and risk profile are yet to be adequately defined. OBJECTIVE: To evaluate the occurrence of sleep disturbances in SLE patients subjected to i.v. cyclophosphamide. METHODS: We studied thirty consecutive SLE patients (27 female) age range 14 to 53 years (mean 30.5 ± 10 years) that received i.v. cyclophosphamide (mg) (mean 948.27 ± 221.39). Depressive symptoms, quality of sleep, and the presence of excessive daytime sleepiness were evaluated. Disease severity was assessed by the SLEDAI. Quality of sleep was assessed by the Pittsburgh Sleep Quality Index (PSQI) and excessive daytime sleepiness (EDS) by the Epworth Sleepiness Scale (ESS). Depressive symptoms were evaluated using the 21-item Beck Depression Inventory (BDI). RESULTS: SLEDAI values ranged from 2 to 46 (mean 17 ± 11.4). The most common comorbidities were systemic arterial hypertension (30%), anemia (23.3%), osteoporosis (23.3%), and cardiomyopathy (6.6%). Seizures occurred in one patient (3.3%). Poor quality of sleep (PSQI e" 6) and EDS (ESS >10) were found in 66.7% and 30% of the patients, respectively. Depressive symptoms (BDI >19) were present in 40% of the patients and were associated with poor sleep quality (P = 0.03). CONCLUSIONS: Our findings show an increased prevalence of poor sleep quality and depressive symptoms in SLE patients receiving pulse i.v. cyclophosphamide. These findings were similar to other previously reported series of SLE patients regardless of the therapies used.
id SBR-1_64537c271bd928518fa145022f6e58d6
oai_identifier_str oai:scielo:S0482-50042007000600002
network_acronym_str SBR-1
network_name_str Revista Brasileira de Reumatologia (Online)
repository_id_str
spelling Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamidelupussleepcyclophosphamideSLEDAIhypersomnolencedepressionBACKGROUND: Pulse i.v. cyclophosphamide is a therapeutic option in severe forms of systemic lupus erythematosus (SLE). However, the overall toxicity and risk profile are yet to be adequately defined. OBJECTIVE: To evaluate the occurrence of sleep disturbances in SLE patients subjected to i.v. cyclophosphamide. METHODS: We studied thirty consecutive SLE patients (27 female) age range 14 to 53 years (mean 30.5 ± 10 years) that received i.v. cyclophosphamide (mg) (mean 948.27 ± 221.39). Depressive symptoms, quality of sleep, and the presence of excessive daytime sleepiness were evaluated. Disease severity was assessed by the SLEDAI. Quality of sleep was assessed by the Pittsburgh Sleep Quality Index (PSQI) and excessive daytime sleepiness (EDS) by the Epworth Sleepiness Scale (ESS). Depressive symptoms were evaluated using the 21-item Beck Depression Inventory (BDI). RESULTS: SLEDAI values ranged from 2 to 46 (mean 17 ± 11.4). The most common comorbidities were systemic arterial hypertension (30%), anemia (23.3%), osteoporosis (23.3%), and cardiomyopathy (6.6%). Seizures occurred in one patient (3.3%). Poor quality of sleep (PSQI e" 6) and EDS (ESS >10) were found in 66.7% and 30% of the patients, respectively. Depressive symptoms (BDI >19) were present in 40% of the patients and were associated with poor sleep quality (P = 0.03). CONCLUSIONS: Our findings show an increased prevalence of poor sleep quality and depressive symptoms in SLE patients receiving pulse i.v. cyclophosphamide. These findings were similar to other previously reported series of SLE patients regardless of the therapies used.Sociedade Brasileira de Reumatologia2007-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042007000600002Revista Brasileira de Reumatologia v.47 n.6 2007reponame:Revista Brasileira de Reumatologia (Online)instname:Sociedade Brasileira de Reumatologia (SBR)instacron:SBR10.1590/S0482-50042007000600002info:eu-repo/semantics/openAccessMesquita,Rafael CarvalhoSouza,Lívia Noronha Coelho deBruin,Pedro Felipe Carvalhedo deCarvalho,Raquel RibeiroMedeiros,Marta Maria das ChagasRocha,Francisco Airton Castro daBruin,Veralice Meireles Sales deeng2008-01-31T00:00:00Zoai:scielo:S0482-50042007000600002Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0482-5004&lng=pt&nrm=isoONGhttps://old.scielo.br/oai/scielo-oai.php||sbre@terra.com.br1809-45700482-5004opendoar:2008-01-31T00:00Revista Brasileira de Reumatologia (Online) - Sociedade Brasileira de Reumatologia (SBR)false
dc.title.none.fl_str_mv Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
title Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
spellingShingle Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
Mesquita,Rafael Carvalho
lupus
sleep
cyclophosphamide
SLEDAI
hypersomnolence
depression
title_short Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
title_full Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
title_fullStr Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
title_full_unstemmed Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
title_sort Sleep disturbances and prevalence of depression in systemic lupus erythematosus patients receiving intravenous cyclophosphamide
author Mesquita,Rafael Carvalho
author_facet Mesquita,Rafael Carvalho
Souza,Lívia Noronha Coelho de
Bruin,Pedro Felipe Carvalhedo de
Carvalho,Raquel Ribeiro
Medeiros,Marta Maria das Chagas
Rocha,Francisco Airton Castro da
Bruin,Veralice Meireles Sales de
author_role author
author2 Souza,Lívia Noronha Coelho de
Bruin,Pedro Felipe Carvalhedo de
Carvalho,Raquel Ribeiro
Medeiros,Marta Maria das Chagas
Rocha,Francisco Airton Castro da
Bruin,Veralice Meireles Sales de
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Mesquita,Rafael Carvalho
Souza,Lívia Noronha Coelho de
Bruin,Pedro Felipe Carvalhedo de
Carvalho,Raquel Ribeiro
Medeiros,Marta Maria das Chagas
Rocha,Francisco Airton Castro da
Bruin,Veralice Meireles Sales de
dc.subject.por.fl_str_mv lupus
sleep
cyclophosphamide
SLEDAI
hypersomnolence
depression
topic lupus
sleep
cyclophosphamide
SLEDAI
hypersomnolence
depression
description BACKGROUND: Pulse i.v. cyclophosphamide is a therapeutic option in severe forms of systemic lupus erythematosus (SLE). However, the overall toxicity and risk profile are yet to be adequately defined. OBJECTIVE: To evaluate the occurrence of sleep disturbances in SLE patients subjected to i.v. cyclophosphamide. METHODS: We studied thirty consecutive SLE patients (27 female) age range 14 to 53 years (mean 30.5 ± 10 years) that received i.v. cyclophosphamide (mg) (mean 948.27 ± 221.39). Depressive symptoms, quality of sleep, and the presence of excessive daytime sleepiness were evaluated. Disease severity was assessed by the SLEDAI. Quality of sleep was assessed by the Pittsburgh Sleep Quality Index (PSQI) and excessive daytime sleepiness (EDS) by the Epworth Sleepiness Scale (ESS). Depressive symptoms were evaluated using the 21-item Beck Depression Inventory (BDI). RESULTS: SLEDAI values ranged from 2 to 46 (mean 17 ± 11.4). The most common comorbidities were systemic arterial hypertension (30%), anemia (23.3%), osteoporosis (23.3%), and cardiomyopathy (6.6%). Seizures occurred in one patient (3.3%). Poor quality of sleep (PSQI e" 6) and EDS (ESS >10) were found in 66.7% and 30% of the patients, respectively. Depressive symptoms (BDI >19) were present in 40% of the patients and were associated with poor sleep quality (P = 0.03). CONCLUSIONS: Our findings show an increased prevalence of poor sleep quality and depressive symptoms in SLE patients receiving pulse i.v. cyclophosphamide. These findings were similar to other previously reported series of SLE patients regardless of the therapies used.
publishDate 2007
dc.date.none.fl_str_mv 2007-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042007000600002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042007000600002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0482-50042007000600002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Reumatologia
publisher.none.fl_str_mv Sociedade Brasileira de Reumatologia
dc.source.none.fl_str_mv Revista Brasileira de Reumatologia v.47 n.6 2007
reponame:Revista Brasileira de Reumatologia (Online)
instname:Sociedade Brasileira de Reumatologia (SBR)
instacron:SBR
instname_str Sociedade Brasileira de Reumatologia (SBR)
instacron_str SBR
institution SBR
reponame_str Revista Brasileira de Reumatologia (Online)
collection Revista Brasileira de Reumatologia (Online)
repository.name.fl_str_mv Revista Brasileira de Reumatologia (Online) - Sociedade Brasileira de Reumatologia (SBR)
repository.mail.fl_str_mv ||sbre@terra.com.br
_version_ 1750318048768688128